A5018709693- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Venous Thromboembolism Diagnosis and Management
- Coronary Interventions and Diagnostics
- Cardiac Arrest and Resuscitation
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Lipoproteins and Cardiovascular Health
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiac electrophysiology and arrhythmias
- Inflammatory mediators and NSAID effects
- Chemotherapy-induced cardiotoxicity and mitigation
- Ultrasound in Clinical Applications
- Cardiac, Anesthesia and Surgical Outcomes
- Angiogenesis and VEGF in Cancer
- Platelet Disorders and Treatments
- Infective Endocarditis Diagnosis and Management
- Cancer Immunotherapy and Biomarkers
- Cardiovascular Function and Risk Factors
- Inflammasome and immune disorders
- Receptor Mechanisms and Signaling
Hôpital Nord
2015-2024
Aix-Marseille Université
2015-2024
Université Toulouse III - Paul Sabatier
2024
Assistance Publique Hôpitaux de Marseille
2013-2023
Unité de recherche sur les maladies cardiovasculaires et métaboliques
2018-2022
Inserm
2016-2021
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
2020
Alliance nationale pour les sciences de la vie et de la santé
2019
Université de Lille
2019
Institut Pasteur de Lille
2019
Post-treatment platelet reactivity (PR) is associated with ischemic and bleeding events in patients receiving P2Y12 receptor antagonists.We aimed to study the relationship between post-treatment PR after a 60-mg loading dose (LD) of prasugrel 1-year thrombotic events.Patients were prospectively included this multicenter if they had successful percutaneous coronary intervention (PCI) for acute syndrome (ACS) received prasugrel. The index (PRI) was measured using Vasodilator-Stimulated...
Background Myocarditis is a rare but life-threatening adverse event of cancer treatments with immune checkpoint inhibitors (ICIs). Recent guidelines recommend the use high doses corticosteroids as first-line treatment, followed by intensified immunosuppressive therapy (IIST) in case unfavorable evolution. However, this strategy empirical, and no studies have specifically addressed issue. Therefore, we aimed to investigate compare clinical course, management outcome ICI-induced myocarditis...
Optimal P2Y12 receptor blockade is critical to prevent ischaemic recurrence in patients undergoing percutaneous coronary intervention (PCI). We aimed compare the level of platelet reactivity (PR) inhibition achieved by prasugrel and ticagrelor loading dose (LD) diabetic acute syndrome (ACS) PCI. performed a single-center prospective open-label randomised trial. Patients with diabetes mellitus PCI for an ACS were receive 60 mg or 180 mg. The primary endpoint study was assessed between 6 18...
Abstract Background Long-term outcomes of lung transplantation (LTx) remain hampered by chronic allograft dysfunction (CLAD). Matrix metalloproteinase 9 (MMP-9) is a secretory endopeptidase identified as key mediator in fibrosis processes associated with CLAD. The objective this study was to investigate whether plasma MMP9 levels may be prognostic CLAD development. Methods Participants were selected from the Cohort Lung Transplantation (COLT) for which biocollection associated. We considered...
Summary Optimal platelet reactivity (PR) inhibition is critical to prevent thrombotic events in primary percutaneous coronary intervention (PCI). We aimed determine the relationship between high on-treatment (HTPR) and ST-elevation myocardial infarction (STEMI) following a 600 mg loading dose (LD) of clopidogrel. performed prospective monocentre study enrolling patients on clopidogrel undergoing PCI. The VASP index was used assess PR after LD. HTPR defined according consensus as ≥50%....
Summary Pretreatment with a loading dose (LD) of clopidogrel or ticagrelor before percutaneous coronary intervention (PCI) in acute syndrome (ACS) is supported by the guidelines, but debated following recent meta-analysis on pretreatment and ACCOAST trial. In this trial prasugrel failed to reduce ischaemic events. The timing optimal platelet reactivity (PR) inhibition non ST-elevation ACS (NSTE ACS) yet undetermined. present study, we aimed investigate delay required reach PR NSTE LD...
Prasugrel and ticagrelor are potent P2Y12-ADP receptor antagonists which superior to clopidogrel in acute coronary syndromes. To date no clinical trial directly compared these two drugs. Platelet reactivity correlates with ischemic bleeding events patients undergoing percutaneous intervention. Recent pharmacological studies have observed a delayed onset of action drugs ST-segment elevation myocardial infarction (STEMI). We provide the first adequately powered study comparing PR following...
Thromboembolic complications associated with infection by Mycobacterium tuberculosis have been reported in the literature that occurred 1.5–3.4% of TB infection, which is a risk factor for deep vein thrombosis (DVT) related to hypercoagulable state secondary inflammatory state. We report this study pathophysiological, therapeutic, epidemiological, and clinical aspects, association. This retrospective done our department between January 2010 May 2013. It about 30 cases confirmed pulmonary...
Impaired vascular tone plays an important role in cardiogenic shock. Doppler echocardiography provides a non-invasive estimation of systemic resistance. The aim the present study was to compare with transpulmonary thermodilution method for assessment resistance patients shock.This prospective monocentric comparison conducted single cardiology intensive care unit (Hopital Nord, Marseille, France). We assessed index by both and 28 admitted shock, on admission after introduction inotrope or...